Basel biotech Windward seeks Nasdaq listing to back Chinese-sourced and internal programs
Windward Bio, a Basel-based biotech founded roughly two years ago, has filed to go public on Nasdaq. The company holds two clinical-stage assets licensed from China and intends to direct IPO proceeds toward those programs and its own research and development.
Windward Bio, a Basel-based company about two years old, has filed for a Nasdaq initial public offering. Its pipeline includes two clinical-stage assets licensed from China, and it plans to put listing proceeds toward those programs plus its own research and development. The move places a European drug developer’s cross-border licensing approach before public-market investors as it seeks capital for clinical work.
A Nasdaq listing could give Windward more capital to advance its licensed and internal programs, potentially affecting patients if those candidates progress into later testing. Public investors may gain exposure to a cross-border biotech model, while the company’s prospects could depend on clinical results and market conditions.